UNSPSC 51393800: Combination sympathomimetics (adrenergics)

This classification denotes combination drugs and preparations mimic the effects of stimulating postganglionic adrenergic sympathetic nerves, such as drugs that stimulate adrenergic receptors or which act indirectly by provoking the release of adrenergic transmitters, hence the term sympathomimetics and adrenergics. Typical combination sympathomimetic or adrenergic constituients are dextrose, dopamine, isoproterenol, and sodium chloride.

UNSPSC 51393800 Combination sympathomimetics (adrenergics) is a Class code that encompasses pharmaceutical products, but the recent state and local procurement activity under this tag does not align with the code's nominal scope. Seminole County, Florida posted an IFB in June 2026 for Naloxone and Safe Drug Deactivation Systems, which are harm-reduction medical devices and pharmaceutical products rather than sympathomimetics. The county sought 1,900 units of Naloxone and 800 deactivation systems annually with quarterly deliveries to support community health initiatives. This procurement signals that state and local health departments and county public health agencies are actively buying naloxone and related opioid-response products, but the UNSPSC classification appears to be a tagging mismatch rather than a reliable indicator of what is actually being purchased under the code's stated category.

The available record shows limited recent activity that directly corresponds to the code's scope. Seminole County's IFB (60459723LAS, response deadline July 26, 2023) represents the primary documented state and local opportunity under this code in the dataset. The procurement required electronic bid submission through the county's e-Procurement Portal, included E-Verify and drug-free workplace compliance, and carried an initial two-year contract term with an optional one-year renewal. Insurance and federal regulatory requirements applied, with potential FEMA funding involvement. No explicit set-aside designations were noted. Given the mismatch between the code's pharmaceutical classification and the harm-reduction products actually being solicited, business development professionals should verify code accuracy with issuing bodies before pursuing opportunities tagged to this classification.